Silence Therapeutics plc (SLN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '24: 43.3M Q1 '25: 27.7M Q2 '25: 27.2M Q3 '25: 25.8M Q4 '25: 559K Q1 '26: 839K Q2 '26: 615K Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 15M 30M 45M Q4 '24: 31.4M Q1 '25: 18.6M Q2 '25: 21.4M Q3 '25: 23.6M Q4 '25: 344K Q1 '26: 667K Q2 '26: 528K Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Income TTM

-105M -70M -35M 0 35M 70M 105M Q4 '24: -63.3M Q1 '25: -86.1M Q2 '25: -86.7M Q3 '25: -83M Q4 '25: -91.1M Q1 '26: -78.4M Q2 '26: -68.3M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-105M -70M -35M 0 35M 70M 105M Q4 '24: -45.3M Q1 '25: -71.5M Q2 '25: -79.1M Q3 '25: -64.5M Q4 '25: -88.6M Q1 '26: -75M Q2 '26: -60M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 5M 10M 15M Q4 '24: 11.8M Q1 '25: 9.1M Q2 '25: 5.8M Q3 '25: 2.2M Q4 '25: 215K Q1 '26: 172K Q2 '26: 87K Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q4 '24: -67.6M Q1 '25: -70.8M Q2 '25: -87.2M Q3 '25: -72.5M Q4 '25: -62.3M Q1 '26: -65.6M Q2 '26: -42.3M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q4 '24: -67.9M Q1 '25: -71M Q2 '25: -87.4M Q3 '25: -72.6M Q4 '25: -62.3M Q1 '26: -65.6M Q2 '26: -42.3M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '24: 131.9M Q2 '24: 140.2M Q3 '24: 141.2M Q1 '25: 141.7M Q2 '25: 141.7M Q3 '25: 141.7M Q1 '26: 141.7M Q2 '26: 141.7M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.75 -0.50 -0.25 0.00 0.25 0.50 0.75 Q4 '24: -0.33 Q1 '25: -0.51 Q2 '25: -0.56 Q3 '25: -0.46 Q4 '25: -0.63 Q1 '26: -0.54 Q2 '26: -0.44 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.